Administration of recombinant erythropoietin determines increase of peripheral resistances in patients with hypovolemic shock.
Allegra
A
A
Galasso
A
A
Siracusano
L
L
Aloisi
C
C
Corica
F
F
Laganà
A
A
Frisina
N
N
Buemi
M
M
D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011651:Pulmonary Artery; D011994:Recombinant Proteins / Q000627:therapeutic use; D012769:Shock / Q000503:physiopathology / Q000628:therapy*; D014655:Vascular Resistance / Q000187:drug effects*
D011994:Recombinant Proteins; D004921:Erythropoietin; D004280:Dobutamine; D004298:Dopamine